Linda Schellenger to retire after 11 years with Telerx and C3i Healthcare Connections
Telerx, a leader in multichannel engagement of consumers, patients, healthcare professionals and enterprise personnel, today announces the appointment of Global Chief Operating Officer Joel Morse as president of Telerx and C3i Healthcare Connections (a Telerx company).
Morse brings nearly 30 years of leadership experience in business strategy, operations and development to this role, having served as the founder and CEO of C3i, Inc. for more than 20 years. Since the acquisition of C3i by Telerx in June 2014, Morse has led the Global Healthcare Operations and Global Process Excellence teams, overseeing all healthcare operations and ensuring the highest standard of quality across all services and solutions.
“I am humbled and excited by the opportunity to become the next president of Telerx and C3i Healthcare Connections,” said Morse. “We will stay focused on our uncompromising commitment to our clients, and we will challenge ourselves to continue to innovate and deliver state-of-the-art customer engagement solutions that have become synonymous with Telerx and C3i Healthcare Connections. Knowing the passion that our team members bring to their work every day, I’m certain we will continue raising the standard for delivering exceptional solutions and outcomes driving many of the world’s most respected and trusted consumer and healthcare brands.”
Morse succeeds current president, Linda Schellenger, who made the personal decision to retire from her position at the end of the first quarter of 2017. “We are grateful to Linda for her strong leadership of Telerx over the past 11 years, and for her commitment to a ‘people come first’ culture,” said Guy Eiferman, managing director, Healthcare Services & Solutions, Merck. “Linda presided over a period of solid business growth inside and outside the United States, and the expansion of services which have enhanced the ability of Telerx clients to benefit from exceptional customer experiences.”
Schellenger, Morse and the Telerx leadership team have constructed a plan to ensure a seamless transition. “I have no doubt that Joel will leverage his life sciences expertise to further raise the bar for our consumer brand engagement services, and I am fully confident that Joel’s sharp focus on strategy and innovation will launch Telerx and C3i Healthcare Connections into an exciting new era,” said Schellenger.
Telerx, a subsidiary of Merck & Co., Inc., is an industry-leading business process outsourcer specializing in the multichannel engagement of consumers, patients, healthcare professionals and enterprise personnel via a network of global contact centers. Our unique customer-centric approach has made Telerx and C3i Healthcare Connections, a Telerx company, the partner of choice for some of the world’s most trusted brands for more than 30 years. Telerx provides unparalleled 24/7 support to clients in 100 countries speaking 30 different languages. With strategic focus on innovation and regulatory compliance, Telerx handles more than 35 million interactions per year, helping our clients build and protect their brands while maximizing productivity and cost efficiencies. More than 90 percent of the company’s clients are FDA-regulated. Telerx and C3i Healthcare Connections maintain corporate headquarters in King of Prussia, Pa., with additional contact centers in Horsham, Pittston and Wilkes-Barre, Pa.; El Paso, Texas; Kings Mountain, N.C.; Morristown, N.J.; Dalian, China; Hyderabad, India; and Sofia, Bulgaria. For more information visit www.Telerx.com or www.C3iHC.com, and connect with us on Facebook, Twitter and LinkedIn.
For over a century, Merck has been a global health care leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
Media Contact for Telerx and C3i Healthcare Connections:
Stephanie Kensy, 610-455-2767